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Abnormal dopaminergic modulation of
striato-cortical networks underlies
levodopa-induced dyskinesias in humans
Damian M. Herz,1,2 Brian N. Haagensen,1 Mark S. Christensen,1,3,4 Kristoffer H. Madsen,1,5
James B. Rowe,6,7,8 Annemette Løkkegaard2 and Hartwig R. Siebner1,2,9
Dopaminergic signalling in the striatum contributes to reinforcement of actions and motivational enhancement of motor vigour.
Parkinson’s disease leads to progressive dopaminergic denervation of the striatum, impairing the function of cortico-basal ganglia
networks. While levodopa therapy alleviates basal ganglia dysfunction in Parkinson’s disease, it often elicits involuntary move-
ments, referred to as levodopa-induced peak-of-dose dyskinesias. Here, we used a novel pharmacodynamic neuroimaging approach
to identify the changes in cortico-basal ganglia connectivity that herald the emergence of levodopa-induced dyskinesias. Twenty-six
patients with Parkinson’s disease (age range: 51–84 years; 11 females) received a single dose of levodopa and then performed a
task in which they had to produce or suppress a movement in response to visual cues. Task-related activity was continuously
mapped with functional magnetic resonance imaging. Dynamic causal modelling was applied to assess levodopa-induced modu-
lation of effective connectivity between the pre-supplementary motor area, primary motor cortex and putamen when patients
suppressed a motor response. Bayesian model selection revealed that patients who later developed levodopa-induced dyskinesias,
but not patients without dyskinesias, showed a linear increase in connectivity between the putamen and primary motor cortex after
levodopa intake during movement suppression. Individual dyskinesia severity was predicted by levodopa-induced modulation of
striato-cortical feedback connections from putamen to the pre-supplementary motor area (Pcorrected = 0.020) and primary motor
cortex (Pcorrected = 0.044), but not feed-forward connections from the cortex to the putamen. Our results identify for the ﬁrst time,
aberrant dopaminergic modulation of striatal-cortical connectivity as a neural signature of levodopa-induced dyskinesias in
humans. We argue that excessive striato-cortical connectivity in response to levodopa produces an aberrant reinforcement signal
producing an abnormal motor drive that ultimately triggers involuntary movements.
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Introduction
The neurotransmitter dopamine provides a reinforcement
signal in the striatum that facilitates appropriate actions
and suppresses inappropriate actions (Redgrave et al.,
2011). Neurobiologically, this is implemented by inducing
long-lasting plasticity in speciﬁc cortico-striatal synapses,
which results in privileged processing of the reinforced cor-
tico-striatal inputs in the cortico-basal ganglia-thalamo cor-
tical re-entry loops (Calabresi et al., 2007). This decreases
the ‘threshold’ to generate the speciﬁc action in the future
and thus prioritizes competing action programs according
to previous action outcomes and current goals (Redgrave
et al., 2011). Nigro-striatal dopaminergic signalling is also
thought to enhance motor vigour and to establish motor
routines and habits (Robbins and Everitt, 2007; Graybiel,
2008).
In Parkinson’s disease, progressive degeneration of
dopaminergic midbrain neurons results in functional de-
afferentation of the putamen, the main motor input
region of the basal ganglia (Lang and Lozano, 1998a, b).
The dopamine precursor levodopa, usually in combination
with dopamine agonists, remains the standard treatment
for alleviation of motor symptoms in Parkinson’s disease
(Hauser, 2009). However, depending on the dose of levo-
dopa and duration of the disease (Cilia et al., 2014), many
patients with Parkinson’s disease start to experience
disabling motor ﬂuctuations, including involuntary ‘dyskin-
esia’ movements (Ahlskog and Muenter, 2001; Van Gerpen
et al., 2006). These levodopa-induced dyskinesias (LID)
occur most frequently when the dopamine effect reaches
its peak (i.e. peak-of-dose dyskinesia).
Animal models of Parkinson’s disease have shown that
the non-physiological dopaminergic stimulation of the
putamen induces maladaptive plastic changes in the cor-
tico-basal ganglia motor loops, resulting in an excessive
striato-cortical drive during high levels of striatal dopamine
(Cenci and Lundblad, 2006). This excessive network activ-
ity is, however, not contingent on previous action outcomes
as in the healthy brain. Instead, activity largely depends on
the dynamics of levodopa-induced changes in striatal dopa-
mine and the degree of nigro-striatal neurodegeneration be-
cause the de-afferentated putamen is no longer able to store
and release dopamine in a controlled manner (Cenci and
Lundblad, 2006). The prevailing notion is that abnormal
dopaminergic modulation of the cortico-basal ganglia
motor loops underlies the emergence of LID (Obeso
et al., 2000; Cenci and Lundblad, 2006; Calabresi et al.,
2007; Ulusoy et al., 2010). However, this claim has never
been tested in humans, in part because the movement arte-
facts caused by LID severely impairs the quality of brain
imaging data.
To address this issue, we used a novel functional MRI
design to investigate acute changes in neural connectivity
between motor areas in the striatum and cortex in response
to a single dose of levodopa. In patients with Parkinson’s
disease with and without peak-of-dose LID, dynamic
changes in striato-cortical connectivity were assessed with
whole-brain functional MRI, while patients performed a
simple motor task. The task required patients to press a
button with their right or left index ﬁnger or to refrain
from any response (referred to as NoGo) contingent on
three pre-learned arbitrary visual cues. A ﬁrst functional
MRI run was acquired after prolonged withdrawal of
dopaminergic medication had induced a dopamine-depleted
state (‘OFF’). The functional MRI measurements continued
immediately following the intake of 200mg fast-acting sol-
uble levodopa (‘post-levodopa’) before any dyskinetic
movements emerged (Fig. 1). A conventional voxel-wise
comparison revealed that in patients with Parkinson’s dis-
ease who would later develop LID, levodopa triggered ex-
cessive No-Go activity in the pre-supplementary motor area
(preSMA) and the bilateral putamen in the pre-dyskinesia
period (Herz et al., 2014b).
This ﬁnding prompted us to apply a model-based direc-
tional connectivity analysis, called dynamic causal model-
ling (DCM) (Friston et al., 2003), to assess the acute
changes in network connectivity within the cortico-basal
ganglia loops after levodopa intake. Focusing on the time
period preceding LID (i.e. the post-levodopa Scan 1) and
the task context of response inhibition (NoGo), our phar-
macodynamic functional MRI approach allowed for the
ﬁrst time to trace the emergence of abnormal connectivity
patterns preceding LID. We predicted that patients who
would later develop peak-of-dose LID would express an
abnormal enhancement of connectivity in networks con-
necting the putamen and cortex in response to dopamine.
Patients and methods
We included 13 Parkinson’s disease patients with clinically diag-
nosed peak-of-dose choreiform dyskinesias (LID group), and 13
Parkinson’s disease patients without dyskinesias (No-LID
group). None of the patients had biphasic dyskinesias.
Exclusion criteria were tremor, dementia or major psychiatric
illness, implanted pacemakers or other general contra-indication
regarding magnetic resonance, and sedatives or serotonergic
medication. In accordance with the Declaration of Helsinki,
all participants gave their informed consent to the study,
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which was approved by the local ethics committee (study-nr: H-
2-2010-146).
Dyskinesias were assessed using the Uniﬁed Dyskinesia
Rating Scale. Both groups were matched with regard to age,
sex, handedness (Edinburgh Handedness Inventory), educa-
tion, cognitive function (Mini-Mental Status Examination
and Montreal Cognitive Assessment), and impulsive personal-
ity trait (Barratt Impulsiveness Scale, BIS-11). Patients with
LID received a signiﬁcantly higher levodopa-equivalent daily
dose (LEDD) compared to the No-LID group. This difference
was driven by differences in the daily dose of levodopa, while
there were no differences in the doses of dopamine agonists
(Supplementary Table 1). However, LID and No-LID patients
did not differ in disease duration, disease severity [Uniﬁed
Parkinsons Disease Rating Scale-III (UPDRS-III), OFF medica-
tion] or clinical response to levodopa (UPDRS-III ON versus
UPDRS-III OFF medication). Additionally, there was no differ-
ence with regard to the number of patients receiving dopamine
agonists next to levodopa therapy. All details and group com-
parisons of clinical speciﬁcations can be found in
Supplementary Table 1.
Study design
We acquired whole-brain functional MRI scans in the ‘prac-
tical OFF medication state’ after prolonged withdrawal of all
dopaminergic medication and continuously after patients had
received 200mg soluble levodopa + 50mg benserazide
(Madopar Quick, La Roche). Dopaminergic medication was
withdrawn according to six half-lives of the respective medi-
cation and at least 12 h. In case dopamine agonists had to be
stopped several days before the experiment, we simultaneously
increased levodopa dosage to reach a similar level of LEDD.
We chose this relatively rigorous washout phase, because the
response to levodopa is more pronounced after a washout
phase compared to standard treatment (Nutt et al., 1994;
Zappia et al., 1997). Given the long duration response to
levodopa, which builds up and decreases slowly—at least in
earlier stages of the disease (Nutt and Holford, 1996; Hauser
and Holford, 2002)—even our rigorous approach did not lead
to a complete depletion of the effects of all extrinsic dopamine.
Nevertheless, we maintain that our approach applied was suf-
ﬁcient given the purpose of the study. There were no differ-
ences in disease severity (UPDRS-OFF) between groups after
the washout phase, the clinical response to 200mg levodopa
(UPDRS ON versus OFF) was similar in the two groups and
robustly induced dyskinesias in the LID group, but none in the
No-LID group. The time line of functional MRI measurements
is illustrated in Fig. 1. This novel pharmacodynamic functional
MRI design allowed us to map the gradual effect of increasing
dopamine levels on connectivity in cortico-basal ganglia motor
loops before the onset of LID rather than contrasting an ‘ON
medication (dyskinetic)’ with an ‘OFF medication (non-dyski-
netic) state’. Because four patients developed LID already
during the second scan after levodopa intake (post-levodopa
Scan 2), we only used the ﬁrst scan after levodopa intake
(post-levodopa Scan 1) for assessing the gradual network re-
sponse to dopamine in patients with and without the subse-
quent onset of LID. Mean time from application of levodopa
to commencement of functional MRI scans was not different
between groups {post-levodopa Scan 1: LID 13  3min
[mean  standard deviation (SD)] versus No-LID 15  5min,
P = 0.337; post-levodopa Scan 2: LID 32  3min versus No-
LID 33  6min, P = 0.375; independent samples t-tests}.
The event-related functional MRI design used a stimulus-re-
sponse mapping task, in which participants pressed a mouse
button with their right index ﬁnger (Right), left index ﬁnger
(Left), or refrained from any motor response (NoGo) depend-
ing on the shape of the stimulus (triangle, circle, square).
Stimulus-response associations were counterbalanced across
participants and groups. Stimuli were presented for 750 ms
followed by a central ﬁxation cross (jittered between 2250–
3250ms). The mean intertrial interval was 3500 ms. We
used PsychoPy (Peirce, 2007) for stimulus presentation and
assigned equal probability to each stimulus. Each session com-
prised 50 Left, 50 Right and 50 NoGo trials and lasted
9min. All patients performed a training session for 5min
before commencement of MRI scans.
Behavioural analysis
We used a 2  3  2 analysis of variance (ANOVA) with the
factors Group, Run and Task laterality (Left, Right) for ana-
lysis of reaction times and the non-parametric Kruskal-Wallis
test for analysis of accuracy rates to compare groups in the
three conditions (Left, Right, NoGo) and sessions. The
mean  SD is reported for all results, which were thresholded
at P50.05.
MRI
All MRI data were acquired on a 3-T Verio scanner (Siemens)
with a 32-channel head coil. Before functional MRI, we re-
corded a T1-weighted anatomical image (MPRAGE, ﬁeld-of-
view 230mm, slice thickness 0.9mm, repetition time
1900ms, echo time 2.32ms, ﬂip angle 9 sagittal orientation).
The image was co-registered to the functional MRI images,
segmented and normalized to the Montreal Neurological
Institute (MNI) template. The structural images were used to
relate activations observed in the functional MRI analysis to
anatomical brain structures of each individual patient.
We acquired 289 functional T2-echo planar images (EPI;
ﬁeld-of-view 192mm, slice thickness 3.5mm, slice spacing
0.2mm, repetition time 1850ms, echo time 26 ms, ﬂip angle
75, 36 slices, ascending slice acquisition order, whole brain
coverage) in each session. Preprocessing and analysis of MRI
data were carried out using Statistical Parametric Mapping
(SPM8, Revision update number 4667, Wellcome Trust
Centre for Neuroimaging, London, UK) implemented in
MATLAB 7.10.2 (Mathworks). The ﬁrst three volumes were
discarded to allow for T1-equilibrium effects. The remaining
images were realigned to the mean EPI-image of the time-series
to correct for small head movements. The resulting images
were normalized to a standard EPI template based on the
MNI reference brain, resampled to 2  2  2mm voxels, and
smoothed with an isotropic 8mm full-width half-maximum
Gaussian kernel, to allow for intersubject anatomical differ-
ences and allow valid statistical inference according to
Gaussian random ﬁeld theory. Additionally, the data were ﬁl-
tered in the temporal domain using a high-pass ﬁlter with a
frequency of 1/128Hz to correct for baseline drifts. We rigidly
controlled the functional MRI data for head movements by
visual inspection. Additionally, we computed the number of
images that were moved 41mm in relation to the previous
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image. This affected only 0.17% of all images, conﬁrming that
participants did not develop involuntary head movements
during the scan, e.g. induced by tremor or dyskinesias.
The statistical analysis of functional MRI data was per-
formed using the general linear model. The design matrix
was generated with the canonical haemodynamic response
function. Regressors of interest comprised Right, Left and
NoGo along with their ﬁrst-order (linear) time-modulation,
since we expected a linear increase in neural activity after
levodopa intake. Twenty-four regressors were computed
based on an expansion of the movement parameters estimated
during realignment and included as nuisance covariates in the
design matrix to remove residual movements artefacts with
spin history effects. Additionally, we included recordings of
respiration and cardiac pulsation as nuisance covariates
(Lund et al., 2006). Controlling for physiological noise is par-
ticularly important in pharmacological functional MRI studies,
since analysis of neural activity is sensitive to drug-induced
changes in physiological parameters (Khalili-Mahani et al.,
2013). In the current study there were no overall differences
between groups (LID, No-LID) or sessions (OFF, ON1, ON2)
in pulse rate [mean: 74/min  12 (SD); Effect of Session:
P = 0.314; Effect of Group: P = 0.44; Interaction: P = 0.155,
ANOVA] or respiration frequency (mean: 16/min  4; Effect
of Session: P = 0.072; Effect of Group: P = 0.58; Interaction:
P = 0.588, ANOVA].
Prior to conducting connectivity analyses, we analysed ab-
normal dopamine-induced changes in neural activity as a func-
tional localizer for the regions of interest of the connectivity
analyses. To this end, we compared task-related activity re-
ﬂecting the linear time-modulation, i.e. the linear changes
over time, of right button presses (Right), left button presses
(Left) and NoGo in the post-levodopa Scan 1 between the LID
and No-LID group using independent samples t-tests. The
results of these analyses identiﬁed the preSMA (centred at x,
y, z: 4, 8, 58; MNI coordinates) and the bilateral putamen
(x, y, z: 28 8 6 and 34 0 4, respectively) as the neural
regions, which expressed an enhanced linear increase in activ-
ity in LID compared to No-LID patients. This difference was
only observed during NoGo, while there were no differences
during Left and Right. Thus, analysis of task-related activity
identiﬁed preSMA and bilateral putamen as the brain regions
and the NoGo condition as the context, in which the LID and
No-LID group showed differential modulation by dopamine.
Furthermore, analysis of main effects of Left, Right and NoGo
guided the speciﬁcations of DCM parameters (see below). The
results related to this functional localizer along with further
analyses of neural activity are reported in detail in a compan-
ion paper (Herz et al., 2014b).
Dynamic causal modelling
DCM was conducted to assess causality and directionality of
neural networks and their dynamic modulation by dopamine
in patients with and without LID (Friston et al., 2003). DCM
examines the instantaneous rates of changes in neural activity
in response to inputs (an experimental perturbation such as
right button presses or activity in another area) underlying
the observed changes in the blood-oxygen level-dependent
signal using a set of differential equations, comprising an A-
matrix (baseline-coupling between regions, which is constant
during the task), a B-matrix (modulation of coupling between
regions by an external input; here linear changes during
NoGo), and a C-matrix (direct inputs to regions; here the dif-
ferent conditions: Left, Right and NoGo) as well as a neuro-
vascular forward model. The neurovascular or haemodynamic
forward model assumes a physiologically veriﬁed increase in
vasodilation and blood ﬂow in the activated region resulting in
Figure 1 Study design. All patients were in a practical ‘OFF-state’ during the initial scans (OFF session). In each session, the motor task was
followed by a 5 min pause to avoid fatigue. After the OFF scan, patients received 200 mg of fast-acting soluble levodopa (Madopar Quick, La
Roche) and the MRI scan was continued immediately with the same order of scans as in the OFF (post-levodopa Scan 1 – pause – post-levodopa
Scan 2). The time elapsing between application of levodopa and initiation of the functional post-levodopa scans was 15 min and did not differ
between groups. A medical doctor (D.M.H.) was continuously present inside the scanner room during MRI acquisition to visually observe whether
LID emerged after levodopa intake. Data acquisition was discontinued as soon as patients developed LID. This enabled us to capture the
progressively emerging neural response to levodopa in patients with Parkinson’s disease without the problem of dyskinesia-related movement
artefacts. For patients that did not develop apparent LID inside the scanner MRI recordings were stopped after two post-levodopa sessions
(i.e. 45 min after levodopa intake). We assessed the dopaminergic modulation of neural network connectivity only in the scan immediately
following levodopa intake (post-levodopa Scan 1, see shaded area), because four patients already developed dyskinesias in the second scan after
levodopa intake (post-levodopa Scan 2). fMRI = functional MRI.
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a change in blood volume and deoxyhaemoglobin content
causing the observed changes in the blood-oxygen level-de-
pendent signal. It is constrained to neurovascular physiology
by empirical priors and accommodates variations in the hae-
modynamic response function by optimizing parameters for
each subject and modelled region (Daunizeau et al., 2011).
Based on the results from the functional localizer (Herz
et al., 2014b), we constructed a parsimonious model compris-
ing preSMA and bilateral putamen, as well as bilateral M1 as
the region responsible for movement execution (Picard and
Strick, 2001). The functional MRI time series were extracted
from the respective regions 5mm in radius from each subject
using the ﬁrst eigenvariate. The coordinates of the regions were
based on the functional MRI results of neural activity (Herz
et al., 2014b) (Supplementary Table 2). For each individual
participant the respective contrast maps were thresholded at
Puncorrected = 0.05 and the coordinates were moved to the acti-
vation maxima closest to the group maximum. To ensure that
the new coordinates were localized in the correct anatomical
region, activation maxima were overlaid on the individual co-
registered structural images and visually controlled. The result-
ing mean coordinates are shown in Supplementary Table 2. In
the DCM, all considered regions shared reciprocal connections
except preSMA and M1 (A-matrix) (Picard and Strick, 2001).
We considered all events in the model. The direct input (C-
matrix) to the regions was deﬁned as the onset of Left, Right
and NoGo. These entered the network via the regions, which
were activated during the respective conditions (i.e. main ef-
fects of Left, Right and NoGo in the analysis of neural activity
(Herz et al., 2014b). Thus, the ‘Left’ cue entered the network
via right M1, the ‘Right’ cue entered the network via left M1,
and the ‘NoGo’ cue entered the network via preSMA and bi-
lateral putamen. The driving inputs to both motor cortices are
likely to be mediated by unmodelled regions, such as premotor
areas, but enter the modelled network via M1. The modula-
tory input (B-matrix) was deﬁned by the linear time-modula-
tion of NoGo-trials during post-levodopa Scan 1. The latter
parameter thus served as a surrogate regressor for the effect of
levodopa during NoGo-trials.
We created a set of network models to assess which cortico-
striatal connections were modulated by levodopa. This analysis
step was not exploratory, but tested speciﬁc a priori deﬁned
hypotheses based on the results of changes in neural activity
underlying development of LID (Herz et al., 2014b). Therefore
we did not specify all potential models, but speciﬁed models
sufﬁcient to test our key hypotheses with a systematic explor-
ation of neighbouring model space. The models differed with
regards to whether (i) levodopa modulated feedforward con-
nections from the cortex to the putamen, feedback connections
from the putamen to the cortex or both (reciprocal); and (ii)
connections between putamen and preSMA, between putamen
and M1 or between putamen and both preSMA and M1 were
modulated. Together with a null-model postulating that no
connections were modulated by levodopa, this resulted in 10
models that were constructed (Fig. 2A). The models were then
estimated for each patient using an expectation maximization
algorithm and compared using Bayesian model selection for
ﬁxed effects. The ﬁxed effects analysis assumes that the
model structure is the same for each subject (within a
group), but the modulation of the coupling can show intersub-
ject variations. Bayesian model selection compares the different
models with regard to their likelihood of explaining the data,
taking into account model complexity (for details see Penny
et al., 2004). We can evaluate whether the best model signiﬁ-
cantly outperforms the other considered models by calculating
the difference in relative log-evidence/free energy. A difference
in relative log evidence/free energy of4 5 is considered ‘very
strong evidence’ and corresponds to a posterior probability of
499% that the winning model generated the data given the
model space (Raftery, 1995; Penny et al., 2004). Prior to con-
ducting Bayesian model selection we ensured that no outliers
were present using Grubbs test. For completeness, we also
conducted Bayesian model selection for random effects
(Stephan et al., 2009). The best model of the LID group was
then used to extract connectivity values from each patient for
regression analysis.
Prediction of severity of dyskinesias
Finally, to test whether dopaminergic modulation of connect-
ivity predicted the severity of emerging LID, we applied linear
regression analysis. To speciﬁcally assess predictions related to
dopaminergic modulation of neural connectivity (in contrast to
changes in neural activity), we entered the connectivity values
of the DCM reﬂecting levodopa-modulation of connectivity (B-
matrix) into a hierarchical multiple linear regression model, in
which the coupling values were added into a regression model
containing modulation of neural activity (preSMA and puta-
men, based on the functional localizer). We entered each of the
connectivity values reﬂecting dopaminergic modulation of
striato-cortical connectivity (putamen-to-preSMA, putamen-
to-M1, preSMA-to-putamen, M1-to-putamen) into the regres-
sion model starting with the variable explaining most variance
(Scheller et al., 2013; Herz et al., 2014a). In the next step, the
variable explaining second most variance was added, etc. and
the improvement of predictions of LID assessed in each step by
computing the changes in R-square. Since LID always ﬁrstly
emerged on the side that was most affected by Parkinson’s
disease, we extracted coupling values of the most affected
hemisphere of each individual patient. The results were thresh-
olded at P = 0.05. To correct for the extra variables entered
into the model we applied the Bonferroni method (Mundfrom
et al., 2006).
Results
Patients reported no problems to perform the task. Patients
showed high accuracy rates of 96% or more, which were
not modulated by group, task, or session (Kruskal-Wallis
tests: all Puncorrected4 0.1). Patients with peak-of-dose dys-
kinesias (LID group) and patients without a history of dys-
kinesias (No-LID group) showed comparable reaction times
for visually cued button presses (No-LID: 684  92 ms;
mean  SD; LID 673  103 ms). This was conﬁrmed by
analysis of variance (ANOVA), which revealed no main
effects of group (P = 0.432), session (P = 0.286), or task
(P = 0.356) on mean reaction time and no signiﬁcant inter-
actions. These ﬁndings indicate that differences in network
connectivity were not driven by differences in task
performance.
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After intake of 200mg levodopa, 10 of 13 patients of the
LID group developed dyskinesias while lying inside the
scanner (i.e. during the functional MRI experiment). In
the remaining three patients, dyskinesias emerged after
they had left the scanner room (i.e. after the end of the
functional MRI experiment). Four LID patients developed
dyskinesias already after post-levodopa Scan 1, i.e.
30min after levodopa intake. Therefore, only the ﬁrst
post-levodopa scan was used for assessing the gradual
network response to dopamine (Fig. 1).
To explore the modulation of cortico-striatal connectiv-
ity, we applied model-based directional connectivity ana-
lysis. This DCM method (Friston et al., 2003) has been
shown to be reliable in older adults and sensitive to the
effects of Parkinson’s disease (Rowe et al., 2010; Michely
et al., 2015) giving directional cortico-subcortical connect-
ivity parameters for the motor system that correlate with
both cortico-subcortical structural connectivity and behav-
iour (Herz et al., 2014a; Rae et al., 2015). We applied
Bayesian model selection for ﬁxed effects (Penny et al.,
2004) to compare several network models, which differed
with regard to the connections that were modulated by
dopamine (Fig. 2A). We found a clear difference between
the most likely models in the LID and No-LID groups. The
network model postulating dopaminergic modulation of re-
ciprocal connectivity between the putamen and preSMA as
well as the putamen and M1 (Model 9) emerged as the
most likely model in patients who later developed LID
with a posterior probability of 499% (difference in free
energy of Model 9 compared to the next best model: 500).
In contrast, for patients who did not develop LID, the
model postulating modulation of reciprocal connectivity be-
tween the putamen and preSMA, but not M1 (Model 7)
exceeded the probability of all other models with a poster-
ior probability of 499% (difference in free energy of
Model 7 compared to the next best model: 1885). The
DCM results are illustrated in Fig. 2B–D (see also
Supplementary Table 3 for estimated parameters of the
respective models). Bayesian model selection for random
effects produced consistent results, namely the highest
exceedance probability (i.e. the probability of a given
model being more likely than any other model considered)
for Model 9 in the LID group (0.43) and Model 7 in the
No-LID group (0.34).
These results indicate that only in patients who later
developed LID, but not in the No-LID group, levodopa
gradually increased connectivity between putamen and
M1 during the 20min after levodopa intake.
In a ﬁnal step, we applied regression analysis to test
whether this dynamic network reorganization following
levodopa predicted the individual severity of LID. For
each patient of the LID group, we extracted the estimated
coupling values reﬂecting levodopa-induced changes in net-
work connectivity (B-matrix in DCM) based on the best
Figure 2 Model-based connectivity analysis. (A) Models that were constructed and compared within the DCM framework. We also
constructed a null model (Model 10) postulating that no connections were modulated by dopamine (not shown). (B) Results of Bayesian model
selection in the LID group. Model 9 had a far higher likelihood than any other model considered resulting in a posterior probability of 499%.
Model 9 explained on average 14.5% variance in the LID group. (C) Result of Bayesian model selection in the No-LID group. Here, Model 7 was far
superior than any other models considered with a posterior probability of 499%. Model 7 explained on average 12.9% variance in the No-LID
group. (D) Best network models of the LID (left) and No-LID (right) group. Driving inputs entered the network via the regions, which were
activated during the respective conditions (right: left M1; left: right M1; NoGo: preSMA, left putamen, right putamen). Note that driving inputs to
both motor cortices are likely to be mediated by unmodelled regions, such as premotor areas, but enter the modelled network via M1.
Connectivity, which showed a linear time modulation during NoGo-trials (B-matrix), is indicated by black arrows, while unmodulated (baseline)
coupling (A-matrix) is indicated by grey arrows.
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model (Model 9). We then entered these values into a hier-
archical multiple linear regression model. The individual
connectivity estimates were added to a regression model
only containing activity changes (preSMA and putamen,
see ‘Patients and methods’ section) to speciﬁcally assess the
associations between acute levodopa induced changes in
neural connectivity and LID severity. Entering coupling
values of ‘feedback’ connections from putamen to preSMA
(Pcorrected = 0.020) and M1 (Pcorrected = 0.044), respectively
signiﬁcantly improved the proportion of explained variance
in individual LID scores as opposed to a model only contain-
ing modulation of neural activity. Modulation of neural con-
nectivity improved predictions of LID severity by22% (R2-
change = 0.218) resulting in prediction of 93%
(R2 = 0.928, adjusted R2 = 0.877) of inter-individual vari-
ance in LID scores based on a multiple regression model con-
taining levodopa-induced modulation of neural activity and
connectivity. This is illustrated in Fig. 3. In contrast, inclusion
of levodopa-induced changes in ‘feedforward’ connectivity
from preSMA and M1 to the putamen did not signiﬁcantly
improve the proportion of explained variance (Pcorrected = 1).
Dopaminergic modulation of striato-cortical connectivity did
not correlate with UPDRS-OFF scores or disease duration
(all Puncorrected4 0.1).
Discussion
In this study, we pharmacologically induced acute changes
in effective connectivity with a single dose of the dopamine
precursor levodopa and traced the dynamic changes in ef-
fective connectivity between the putamen and key cortical
motor areas in the pre-dyskinesia period. This novel dy-
namic functional MRI approach revealed for the ﬁrst
time, an abnormal dopaminergic modulation of striato-
cortical connectivity in patients who suffer from LID com-
pared to Parkinson’s disease patients without LID. Indeed,
the effect of levodopa on neural activity and connectivity
accurately predicted the severity of subsequent LID
(R24 0.9).
Reinforcement of speciﬁc connections between the cortex
and basal ganglia is mediated by neural plasticity, in par-
ticular long-term potentiation, in the synapses projecting
onto the medium-spiny neurons in the putamen (Calabresi
et al., 2007). Long-term potentiation is induced when
dopamine, which is released from the endings of dopamin-
ergic nigro-striatal projections, and glutamate, which is
released by cortico-striatal projections, simultaneously acti-
vate the medium-spiny neurons in the putamen (Calabresi
et al., 2007). During progression of Parkinson’s disease,
the ability to release dopamine in a controlled manner is
severely affected, which leads to an abnormal induction of
long term potentiation at the cortico-striatal synapse when
patients take their dopaminergic medication (Cenci and
Lundblad, 2006). Such a mechanism is thought to cause
an aberrant enhancement of striato-cortical connections
leading to emergence of LID. This hypothesis is supported
by studies in animals demonstrating an aberrant regulation
of long-term potentiation in rats with dyskinesias (Picconi
et al., 2003; Iravani and Jenner, 2011) and studies using
transcranial magnetic stimulation showing abnormal plas-
ticity-like effects in the motor cortex of dyskinetic
Parkinson’s disease patients (Morgante et al., 2006;
Huang et al., 2011).
Our connectivity analysis provides strong in vivo support
to the notion that excessive striatal responsiveness to levo-
dopa and aberrant striato-cortical connectivity are key
mechanisms underlying peak-of-dose LID in patients with
Parkinson’s disease. We demonstrate that intake of levo-
dopa triggers an abnormal modulation of neural connect-
ivity between putamen and frontal cortical areas in patients
Figure 3 Dopaminergic modulation of neural networks
predicts severity of involuntary movements. The figure illus-
trates that mapping of the neural network reorganization after
dopamine intake allowed precise predictions about the severity of
LID even before they emerged. Top: Red spheres indicate changes in
activity of preSMA and putamen, which were related to the emer-
gence of LID. Red arrows indicate that feedback connectivity from
the putamen to M1 and preSMA significantly improved predictions
of LID compared to a regression model, which only contained
changes in neural activity. Bottom: The panel shows that the hier-
archical multiple linear regression model explained almost 93%
variance of interindividual differences in LID scores.
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with Parkinson’s disease with LID compared to patients
with Parkinson’s disease without LID. Analysis of effective
connectivity using DCM demonstrated that in patients who
later developed LID, a levodopa-induced rise in dopamine
gradually enhanced connectivity between the putamen and
M1. This pharmacodynamic modulation of effective con-
nectivity between putamen and M1 was absent in those
patients with Parkinson’s disease showing a stable clinical
response to levodopa without LID.
The connectivity changes induced by a single dose of
levodopa in patients with Parkinson’s disease with LID dis-
played several features that deserve comment. First, the ab-
normal network response in the LID group was expressed
during NoGo trials. Therefore, we hypothesize that the
increased inﬂuence of the putamen to M1 might reﬂect
an (inappropriate) ‘Go’ signal that gradually emerges des-
pite a cue-response mapping rule requiring movement sup-
pression. Second, the aberrant striato-cortical coupling
emerged very soon, showing a gradual build-up over
20min after levodopa intake. In the current study the
LID group received a signiﬁcantly higher dose of levodopa
compared to the No-LID group. One might therefore
speculate whether the abnormal dopaminergic modulation
of striato-cortical connections in the LID group observed in
this study might be related to an abnormal sensitization of
postsynaptic D1 receptors induced by pulsatile stimulation
and abnormally elevated levels of synaptic dopamine
during levodopa treatment. Third, the emergence of abnor-
mal striato-cortical connectivity predicted the severity of
subsequent LID in a regression model that accounted for
changes in regional activity. This predictive value of the
observed connectivity pattern suggests a causal link be-
tween the levodopa-induced change in striato-cortical con-
nectivity and the manifestation of peak-of-dose LID in our
LID patient cohort. Critically, this abnormal expression of
striato-cortical connectivity was not confounded by differ-
ences in behaviour or the presence of LID. Patients with
and without LID showed no differences in task perform-
ance. Further, we closely monitored that LID patients had
no dyskinesias during data acquisition.
Our ﬁndings are in good agreement with electrophysio-
logical studies suggesting that the clinical effect of dopa-
mine in Parkinson’s disease is mediated by connections
from the basal ganglia to the cortex (Williams et al.,
2002). Regarding the directionality of connectivity changes,
our regression analysis showed that modulation of feed-
back connections from the putamen to preSMA and M1,
but not feedforward connections, strongly predicted sever-
ity of day-to-day symptomatic LID. Furthermore, analysis
of neural connectivity in this study was based on neural
activity recorded during NoGo trials, i.e. trials in which
actions (and thus cortico-striatal connectivity) should not
be facilitated. Even though we cannot disentangle connec-
tions processed via the direct and indirect pathway, respect-
ively, the ﬁnding that connectivity changes related to the
severity of LID were directed from the putamen to cortical
areas indicates that the observed connectivity changes
reﬂect an aberrant reinforcement signal. Such a mechanism
would result in abnormally decreased thresholds to gener-
ate a movement and thus the emergence of involuntary
dyskinesia movements.
In conclusion, we demonstrate for the ﬁrst time abnormal
dopaminergic modulation of striato-cortical connectivity
underlying LID in humans. Our ﬁndings highlight that
dopamine has aberrant effects on the dynamic organization
of neural networks when applied in a non-physiological
manner in patients with Parkinson’s disease. Our pharma-
codynamic functional MRI approach has the potential to
uncover abnormal striato-cortical connectivity patterns in
other brain diseases where symptoms are treated with neu-
romodulatory drugs. In Parkinson’s disease, our approach
might also help to identify patients at risk of developing
side effects to dopaminergic medication by mapping their
individual neural response to dopamine.
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